Association of IGF-1 CA(n) and IGFBP3 rs2854746 Polymorphisms with Endometrial Polyp Risk

Introduction. Insulin-like growth factor 1 (IGF-1) is a peptide growth factor that promotes cell proliferation and inhibits apoptosis. The bioavailability of IGF-1 is regulated by the insulin-like growth factor binding protein 3 (IGFBP3). Genetic variations influence the levels of IGF-1 and IGFBP3....

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2018-01, Vol.2018 (2018), p.1-6
Main Authors: Haimovich, Sergio, Wajman, Milton, Pompei, Luciano Melo, Fernandes, Cesar Eduardo, Tcherniakovsky, Marcos, Moscovitz, Thomas, Doria, Pedro Leopoldo Silva, Nimwegen, Angela Van
Format: Article
Language:English
Subjects:
Adult
Apoptosis
Binding sites
Bioavailability
Cancer
Capillary electrophoresis
Case-Control Studies
Cell growth
Cell proliferation
Confidence intervals
Deoxyribonucleic acid
DNA
Electrophoresis
Endocrinology
Endometrium
Epidemiology
Female
Gene expression
Gene polymorphism
Genetic aspects
Genetic diversity
Genotype
Genotypes
Genotyping
Growth factors
Humans
Insulin
Insulin-Like Growth Factor Binding Protein 3 - genetics
Insulin-like growth factor I
Insulin-Like Growth Factor I - genetics
Insulin-like growth factor-binding protein 3
Insulin-like growth factors
Medical research
Middle Aged
Polymorphism
Polymorphism, Genetic
Polyps
Polyps - genetics
Post-menopause
Postmenopausal women
Protein binding
Proteins
Quality control
Regression analysis
Risk Factors
Statistical analysis
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Insulin-like growth factor 1 (IGF-1) is a peptide growth factor that promotes cell proliferation and inhibits apoptosis. The bioavailability of IGF-1 is regulated by the insulin-like growth factor binding protein 3 (IGFBP3). Genetic variations influence the levels of IGF-1 and IGFBP3. The purpose of this study was to examine the association of polymorphisms IGF-1 CA(n) and IGFBP3 rs2854746 with risk of endometrial polyps. Materials and Methods. Case control observational study, composed of 104 women with antecedent of endometrial polyp (case group) and 81 postmenopausal women without antecedent of endometrial diseases (control group). Genotyping of IGF-1 CA(n) was performed by PCR and fragment analysis by capillary electrophoresis, and genotyping of IGFBP3 rs2854746 was performed by PCR-HRM. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. Results. The genotype IGF-1 CA(19)/CA(19) was associated with an increased endometrial polyp risk (OR=2,57; IC 95%= 1,09 - 6,01); this was also found when combining it with CA(>19)/CA(n) genotypes (OR=2,18; IC 95%= 1,06-4,47). The IGFBP3 rs2854746 analyses showed the CG genotype having a protective effect for endometrial polyp (OR=0,37; IC 95%= 0,19-0,73), fact also observed when grouping CG and GG carriers (OR=0,51; IC 95%= 0,28-0,93). Conclusion. The genotypes CA(19)/CA(19) and CA(19)/CA(19) + CA(>19)/CA(n) of the IGF-1 CA(n) may be considered a risk for endometrial polyp, whereas the genotypes CG and CG + GG of IGFBP3 rs2854746 polymorphism have an inverse effect of endometrial polyp risk.
ISSN:2314-6133
2314-6141
DOI:10.1155/2018/8704346